Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda

Executive Summary

Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval

You may also be interested in...



Schering GMP Work Plan Is One-Third Complete; Toughest Battles Lie Ahead

The remaining two-thirds of Schering-Plough's GMP work plan contain the most challenging requirements under the company's 2002 manufacturing consent decree, CEO Fred Hassan told analysts Nov. 18

Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia

Schering-Plough will begin to reverse cutbacks in its primary care sales force, CEO Fred Hassan told investors during a conference call July 23

Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia

Schering-Plough will begin to reverse cutbacks in its primary care sales force, CEO Fred Hassan told investors during a conference call July 23

Related Content

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel